Yellon, D. M.
~ 800  Ergebnisse:
Personensuche X
?
 
?
2

The selective Rho Kinase 2 inhibitor Chroman-1, is a potent..:

Pearce, L ; Yusof, L ; He, D..
European Heart Journal.  44 (2023)  Supplement_2 - p. , 2023
 
?
7

Troponin trends during anthracycline chemotherapy and their..:

Mallouppas, M ; Chung, R ; Macklin, A...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
 
?
8

P495Investigating SDF-1alpha signalling via CXCR7 receptor ..:

Taferner, S ; Yellon, D M ; Davidson, S M
Cardiovascular Research.  114 (2018)  suppl_1 - p. S120-S120 , 2018
 
?
9

SGLT 2 inhibitor, Canagliflozin attenuates myocardial infar..:

Lim, V.G. ; Bell, R.M. ; Arjun, S....
Journal of Molecular and Cellular Cardiology.  120 (2018)  - p. 27 , 2018
 
?
11

Hearts deficient in both Mfn1 and Mfn2 are protected agains..:

Hall, A R ; Burke, N ; Dongworth, R K...
Cell Death & Disease.  7 (2016)  5 - p. e2238-e2238 , 2016
 
?
 
?
13

Cardioprotective Properties of the Platelet P2Y12 Receptor ..:

Bell, R. M. ; Sivaraman, V. ; Kunuthur, S. P....
Cardiovascular Drugs and Therapy.  29 (2015)  5 - p. 415-418 , 2015
 
?
14

Exogenous SDF-1α Protects Human Myocardium from Hypoxia-Reo..:

Malik, A. ; Bromage, D. I. ; He, Z....
Cardiovascular Drugs and Therapy.  29 (2015)  6 - p. 589-592 , 2015
 
?
 
1-15